Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:6:825-33.
doi: 10.2147/IJN.S18045. Epub 2011 Apr 19.

Application of hydroxyapatite nanoparticles in development of an enhanced formulation for delivering sustained release of triamcinolone acetonide

Saeid Koocheki  1 , Sayed Siavash Madaeni, Parisa Niroomandi
Affiliations

Application of hydroxyapatite nanoparticles in development of an enhanced formulation for delivering sustained release of triamcinolone acetonide

Saeid Koocheki et al. Int J Nanomedicine. 2011.

Abstract

We report an analysis of in vitro and in vivo drug release from an in situ formulation consisting of triamcinolone acetonide (TR) and poly(D,L-lactide-co-glycolide) (PLGA) and the additives glycofurol (GL) and hydroxyapatite nanoparticles (HA). We found that these additives enhanced drug release rate. We used the Taguchi method to predict optimum formulation variables to minimize the initial burst. This method decreased the burst rate from 8% to 1.3%. PLGA-HA acted as a strong buffer, thereby preventing tissue inflammation at the injection site caused by the acidic degradation products of PLGA. Characterization of the optimized formulation by a variety of techniques, including scanning electron microscopy, X-ray diffraction, differential scanning calorimetry, and Fourier transform near infrared spectroscopy, revealed that the crystalline structure of TR was converted to an amorphous form. Therefore, this hydrophobic agent can serve as an additive to modify drug release rates. Data generated by in vitro and in vivo experiments were in good agreement.

Keywords: PLGA; glycofurol; hydroxyapatite nanoparticle; triamcinolone acetonide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Poly(d,l-lactide-co-glycolide) hydrolysis.
Figure 2
Figure 2
Structures of A) triamcinolone acetonide and B) polyethylene glycol ether.
Figure 3
Figure 3
Triamcinolone acetonide release kinetics in poly(d,l-lactide-co-glycolide) in phosphate buffer.
Figure 4
Figure 4
Hydroxyapatite nanoparticles.
Figure 5
Figure 5
Cumulative triamcinolone acetonide release kinetics in poly(d,l-lactide-co-glycolide)-hydroxyapatite in phosphate buffer.
Figure 6
Figure 6
Cumulative TR release kinetics in poly(d,l-lactide-co-glycolide)-hydroxyapatite in phosphate buffer (after 1.5 days).
Figure 7
Figure 7
Effects of variables vs parameter levels.
Figure 8
Figure 8
Effects on pH of triamcinolone acetonide (5%) with PLGA or PLGA-HA. Abbreviations: PGLA, poly(d,l-lactide-co-glycolide); PGLA-HA, poly(d,l-lactide-co-glycolide) with hydroxyapatite.
Figure 9
Figure 9
SEM image of membranes after immersion in phosphate buffer for 20 days: A) poly(d,l-lactide-co-glycolide) and B) PGLA-HA: poly(d,l-lactide-co-glycolide) with hydroxyapatite.
Figure 10
Figure 10
Diffractograms of A) triamcinolone acetonide B) PLGA and triamcinolone acetonide (15%), C) PLGA and triamcinolone acetonide (15%) and polyethylene glycol ether (3%). Abbreviation: PLGA, poly(D,L-lactide-co-glycolide).
Figure 11
Figure 11
Scanning electron microgram of poly(d,l-lactide-co-glycolide) membranes: A) 3% and B) 0% polyethylene glycol ether.
Figure 12
Figure 12
Fourier transform near infrared spectra of poly(d,l-lactide-co-glycolide) membranes in the presence of A) 0%, B) 1%, and C) 3% polyethylene glycol ether.
Figure 13
Figure 13
Hot-plate response of mice (n = 5) administered triamcinolone acetonide.
Figure 14
Figure 14
Hot-plate response of mice (n = 5) administered triamcinolone acetonide with poly(d,l-lactide-co-glycolide).
See this image and copyright information in PMC

References

    1. Kakinoki S, Taguchi T. Antitumor effect of an injectable in-situ forming drug delivery system composed of a novel tissue adhesive containing doxorubicin hydrochloride. Eur J Pharm Biopharm. 2007;67:676–681. - PubMed
    1. Lee F, Chung JE, Kurisawa M. An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. J Control Release. 2009;134:186–193. - PubMed
    1. Fraylich MR, Liu R, Richardson SM, et al. Thermally-triggered gelation of PLGA dispersions: towards an injectable colloidal cell delivery system. J Colloid Interface Sci. 2010;344:61–69. - PubMed
    1. Hollister LE. Site-specific drug delivery to CNS: Old and new. Neurobiol Aging. 1989;10:628–631. - PubMed
    1. Levy RJ, Vinod L, Strickberger SA, Underwood T, Davis J. Controlled release implant dosage forms for cardiac arrhythmias: review and perspectives. Drug Delivery. 1996;3:137–142. - PubMed

Publication types

MeSH terms